A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of patients with PD-L1 positive gastric cancer or gastroesophageal junction adenocarcinoma (≥T3 and the number of lymph node metastasis ≥1, and No distant metastasis) using Toripalimab combined with docetaxel, oxaliplatin, fluorouracil, leucovorin (FLOT regimen) .
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
DRUG: Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
Pathological complete response (pCR), 3 months
event-free survival (EFS), 2 years|disease-free survival (DFS), 2 years|overall survival (OS), 2 years|objective response rate (ORR), 3 months|R0 Surgical conversion rate, 3 months|major pathological response (MPR), 3 months|Incidence and severity of adverse events, 6 months|index of tumor-infiltrating lymphocyte (sTIL) infiltration, 3 months|type and number of intestinal flora, 3 months
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of patients with PD-L1 positive gastric cancer or gastroesophageal junction adenocarcinoma (≥T3 and the number of lymph node metastasis ≥1, and No distant metastasis) using Toripalimab combined with docetaxel, oxaliplatin, fluorouracil, leucovorin (FLOT regimen) .